Depression

Latest News


CME Content


SAN DIEGO, April 2 -- For better or worse, pediatric antidepressant prescriptions dropped 18.6% following an FDA hearing in 2004 that led to a black box warning a month later on an increased suicidality risk, according to researchers here.

BOULDER, Colo. -- Intensive psychotherapy, coupled with medication, speeds recovery from depression for patients with bipolar disorder, according to researchers here.

STANFORD, Calif. -- Despite hopes that selective serotonin reuptake inhibitors can help control kleptomania, a small randomized trial of one agent yielded no more than a placebo response.

INDIANAPOLIS -- Anxiety disorders are as prevalent as depression among patients in primary-care practices, but anxiety often goes untreated, investigators here have found.

SYDNEY, Australia -- The swollen and twisted joints in the hands and feet from rheumatoid arthritis are associated with depression in patients who become unhappy with their physical appearance, researchers here said.

UTRECHT, The Netherlands -- IVF rates for term live births after "mild" ovarian stimulation with single-embryo transfer equaled the rates for standard stimulation with two-embryo transfer, Dutch researchers reported.

abstract: Depression and anxiety are common comorbidities in patients with chronic obstructive pulmonary disease (COPD), and like COPD, they are often underrecognized. Both of these comorbidities can adversely affect the course of COPD. Anxiety, for example, is associated with more severe dyspnea, greater disability, and impaired functional status; it also is a significant predictor of hospitalizations for acute exacerbations of COPD. When evaluating depressive symptoms, it is important to rule out cognitive impairment, particularly in patients with severe COPD and hypoxemia. Treatment options include antidepressants and cognitive behavioral therapy. Participation in a pulmonary rehabilitation program also can help reduce anxiety and depressive symptoms in patients with COPD. (J Respir Dis. 2007;28(3):94-103)

ABSTRACT: Antiplatelet agents used to treat non-ST-segment elevation myocardial infarction (NSTEMI) and unstable angina include aspirin, clopidogrel, and glycoprotein (GP) IIb/IIIa inhibitors. Aspirin is recommended for all patients with acute coronary syndromes (ACS). Clopidogrel can also be used in all patients with ACS, although this agent increases the risk of major bleeding complications if coronary artery bypass grafting is performed less than 5 days after the last dose. Early use of a GP IIb/IIIa inhibitor provides additional benefit in patients with NSTEMI, particularly those who undergo percutaneous coronary intervention. Agents used for anticoagulation in patients with NSTEMI or unstable angina include unfractionated heparin, low molecular weight heparins (LMWHs), and the direct thrombin inhibitor bivalirudin. Enoxaparin-the only LMWH currently indicated for treatment of patients with NSTEMI-can be considered as an alternative to unfractionated heparin, particularly in those who do not require urgent cardiac catheterization.